Metastatic Breast Cancer Treatment After Abemaciclib-Related Liver Injury — Case 1
This breast cancer diagnosis at a glance
- Stage at diagnosis
- Stage IV
- Sex
- female
- Treatment
- hormone therapy and targeted therapy
- Outcome
- Care Ongoing
Treatment course, step by step
- She started letrozole with abemaciclib.
- Abemaciclib was stopped after severe liver injury on day 29 while letrozole continued.
- After liver tests improved, she switched to palbociclib and had no recurrent liver dysfunction.
What happened, in summary
A 72-year-old woman with metastatic breast cancer began letrozole together with abemaciclib. Within 29 days, her ALT rose to 586 IU/L, indicating severe liver injury. Abemaciclib was stopped, while letrozole was continued. Over about 1 month, the ALT level fell by roughly half. Abemaciclib was not restarted. After her liver function improved, she switched to palbociclib so that CDK4/6 inhibitor treatment could continue. Her ALT remained stable after the switch, with no recurrence of the liver dysfunction. The main challenge in her course was maintaining systemic treatment while avoiding another episode of severe liver injury.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- Stage 4 Breast Cancer 295 stories
- Abemaciclib for Breast Cancer 25 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer